Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CEST

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22 JOHNSON & JOHNSON : Canadian Concerns Over Surgical Mesh Recalls and Usage on th..
05/21 JOHNSON & JOHNSON : Talcum powder lawsuits find a home in St. Louis -- for now
05/20 REP. PAYNE ISSUES : Johnson & Johnson's Commitment to Veterans
05/20 Corticosteroids Market 2017 - GSK, Cipla, Sumitomo, Pfizer, Novartis, Merck, ..
05/19 JOHNSON & JOHNSON : Xian Arm Invests More for Lung Diseases
05/19 JOHNSON & JOHNSON : Amey joins businesses campaigning to support social enterpri..
05/18 JOHNSON & JOHNSON : Loses Another Talcum Powder Lawsuit, As Missouri Jury Awards..
05/18 JOHNSON & JOHNSON : Pennsylvania Transvaginal Mesh Lawsuit Plaintiffs Hope to Ex..
05/18 JOHNSON & JOHNSON : RM Global to invest $30m in FutuRx biotech startups
More news
Sector news : Pharmaceuticals - NEC
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/18 NOVARTIS : to cut around 500 jobs in Switzerland, add 350
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/22 'Safer' Dividend Healthcare Dog's 55% Top Gain Equals Sum Of Four Tailing It ..
05/22 RETIREMENT STRATEGY : Yes, I Am A Little Nuts But I Am Doing It Anyway
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
05/21 NEW DIV ON THE BLOCK QUARTERLY EARNI : Part 2
Advertisement
Financials ($)
Sales 2017 75 617 M
EBIT 2017 23 468 M
Net income 2017 17 895 M
Debt 2017 8 113 M
Yield 2017 2,65%
P/E ratio 2017 19,37
P/E ratio 2018 17,40
EV / Sales 2017 4,63x
EV / Sales 2018 4,40x
Capitalization 342 117 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 130 $
Spread / Average Target 2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.23%342 117
ROCHE HOLDING LTD.14.79%235 098
NOVARTIS AG6.28%210 347
PFIZER INC.-0.06%193 303
MERCK & CO., INC.8.34%174 449
SANOFI14.93%124 751
More Results